Apyx Medical Co. (NASDAQ:APYX) Sees Significant Decline in Short Interest

Apyx Medical Co. (NASDAQ:APYX) was the target of a significant drop in short interest during the month of August. As of August 31st, there was short interest totalling 265,100 shares, a drop of 10.7% from the August 15th total of 296,900 shares. Based on an average trading volume of 34,900 shares, the short-interest ratio is currently 7.6 days. Approximately 0.9% of the shares of the company are short sold.

Analyst Ratings Changes

Separately, JMP Securities reiterated a “market perform” rating on shares of Apyx Medical in a research note on Monday.

Apyx Medical Price Performance

NASDAQ:APYX opened at $1.08 on Wednesday. Apyx Medical has a 52 week low of $0.97 and a 52 week high of $4.00. The company has a debt-to-equity ratio of 2.26, a quick ratio of 4.45 and a current ratio of 5.33. The company has a 50-day moving average of $1.27 and a 200-day moving average of $1.43. The company has a market capitalization of $37.42 million, a price-to-earnings ratio of -1.64 and a beta of 1.20.

Apyx Medical (NASDAQ:APYX) last released its quarterly earnings data on Thursday, August 8th. The company reported ($0.19) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.18) by ($0.01). Apyx Medical had a negative return on equity of 105.45% and a negative net margin of 57.86%. The company had revenue of $12.15 million for the quarter, compared to analyst estimates of $12.67 million. During the same quarter in the prior year, the company earned ($0.11) earnings per share. As a group, equities research analysts anticipate that Apyx Medical will post -0.69 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Apyx Medical

A number of institutional investors and hedge funds have recently added to or reduced their stakes in APYX. AIGH Capital Management LLC increased its holdings in shares of Apyx Medical by 7.7% during the fourth quarter. AIGH Capital Management LLC now owns 2,040,540 shares of the company’s stock worth $5,346,000 after buying an additional 145,309 shares in the last quarter. Silverberg Bernstein Capital Management LLC boosted its stake in Apyx Medical by 1.2% in the first quarter. Silverberg Bernstein Capital Management LLC now owns 621,387 shares of the company’s stock worth $845,000 after purchasing an additional 7,507 shares in the last quarter. Worth Venture Partners LLC increased its stake in shares of Apyx Medical by 12.0% in the fourth quarter. Worth Venture Partners LLC now owns 518,198 shares of the company’s stock valued at $1,358,000 after buying an additional 55,592 shares in the last quarter. Commonwealth Equity Services LLC increased its stake in shares of Apyx Medical by 2.9% in the second quarter. Commonwealth Equity Services LLC now owns 511,561 shares of the company’s stock valued at $685,000 after buying an additional 14,481 shares in the last quarter. Finally, Rathbones Group PLC lifted its position in Apyx Medical by 148.0% during the 2nd quarter. Rathbones Group PLC now owns 251,334 shares of the company’s stock worth $337,000 after buying an additional 150,000 shares in the last quarter. 55.33% of the stock is currently owned by institutional investors and hedge funds.

About Apyx Medical

Apyx Medical Corporation, an energy technology company, engages in the design, development, and manufacture of medical devices in the United States and internationally. The company operates through two segments: Advanced Energy and Original Equipment Manufacturing (OEM). It offers Helium Plasma Generator for delivery of RF energy and helium plasma to cut, coagulate, and ablate soft tissue during open and minimally invasive surgical procedures.